Omega Funds

Life sciences investor active in late-stage biotech rounds.

Profile being verified

Stage
Series B and round not specified across recorded rounds
Ticket
Tickets not disclosed; recorded rounds of USD 152 M to USD 165 M
Location
Not specified
Tracked rounds
2

What they look for

Existing investor in Windward Bio since its Series A; participant in Vaderis Therapeutics' Series B, where Francesco Draetta of Omega Funds sits on the board.

Recent investments

Recorded Swiss rounds: Windward Bio (stage not specified, USD 165 M, May 2026), Vaderis Therapeutics (Series B, USD 152 M, August 2026).

Rounds tracked by FundSwiss